Is Compound Tirzepatide Ending? FDA Shortage List Updated 2024

What Is The FDA Shortage List and How It Affect Medication Compounding?

The FDA defines a drug shortage as a period when the demand or projected demand for a medically necessary drug in the United States exceeds its supply. When a shortage occurs, it can lead to the production of compounded medications as an alternative source. Here's a breakdown of the FDA's drug shortage criteria and related information:

Source: U.S. Food and Drug Administration. (2024). Drug Shortages. Retrieved from https://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages
During a shortage, the FDA may allow the temporary distribution of a compounded drug product to meet patient needs. Compounded drugs are not FDA-approved but can serve as alternatives when manufactured drugs are unavailable. The FDA maintains a public database of current drug shortages and works closely with manufacturers to address supply issues and mitigate shortages.

Semaglutide and Tirzepatide on the FDA Drug Shortage List

Semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) are GLP-1 receptor agonists used for treating type 2 diabetes and obesity. Both medications have experienced shortages due to high demand and manufacturing constraints.

Semaglutide (Wegovy)

Wegovy first appeared on the FDA drug shortage list in May 2022. As of August 2024, three doses of Wegovy remain in limited availability:

• 0.25 mg/0.5 mL
• 0.5 mg/0.5 mL
• 1 mg/0.5 mL

The FDA database lists the estimated shortage duration for these doses as "TBD" (To Be Determined).

Tirzepatide (Mounjaro)

Mounjaro was added to the FDA drug shortage list in December 2022. However, as of August 4, 2024, the FDA has updated its drug shortage database to indicate that all doses of Mounjaro and Zepbound (the brand name for tirzepatide approved for weight loss) are now available. This includes:

• 2.5 mg/0.5 mL
• 5 mg/0.5 mL
• 7.5 mg/0.5 mL
• 10 mg/0.5 mL
• 12.5 mg/0.5 mL
• 15 mg/0.5 mL

This recent update suggests that Eli Lilly, the manufacturer of tirzepatide, has successfully increased production to meet demand. However, it's important to note that availability can fluctuate, and patients should consult with their healthcare providers for the most current information regarding access to these medications.

Does This Mean Compounded Tirzepatide Will End?

When a drug shortage is resolved and the medication is removed from the FDA's shortage list, it does not automatically mean that all compound pharmacies will immediately stop making compounded versions of that drug. In the case of tirzepatide, the resolution of the shortage does not legally require compound pharmacies to cease production. However, it typically leads to a significant reduction in compounding activities for that specific medication.

According to the FDA's regulations, compound pharmacies are allowed to produce versions of commercially available drugs primarily when there is a shortage or the commercial product is otherwise unavailable. Once the shortage is resolved, the legal basis for large-scale compounding of that medication becomes less clear. In practice, many compound pharmacies will phase out production of the previously shortage drug over a period of weeks to months.

For tirzepatide specifically, since its removal from the FDA shortage list on August 4, 2024, we can expect to see a gradual decline in compounded versions. Based on historical patterns with similar high-demand medications, it's likely that within 3-6 months after the shortage resolution, the availability of compounded tirzepatide will decrease by 70-80%. However, some compounding may continue on a smaller scale for patients with specific needs that the commercial product doesn't meet, such as those requiring unique dosage forms or those with allergies to inactive ingredients in the FDA-approved version.

What Is The FDA Process To Take Drug Off The Shortage List?

The entire process, from a manufacturer reporting increased supply to the FDA officially resolving the shortage, can take anywhere from a few weeks to several months. For example:

• In 2018, when the shortage of IV fluids was resolved following Hurricane Maria's impact on manufacturing in Puerto Rico, it took approximately 6-8 months from the time manufacturers reported increased production to the FDA declaring the shortage resolved.
• More recently, with COVID-19 related drug shortages, some medications were removed from the shortage list within 2-3 months of manufacturers reporting increased supply, while others took longer.

It's important to note that the FDA's approach is cautious to avoid prematurely declaring a shortage resolved, only to have it recur shortly after. The agency strives to ensure that the supply is truly stable and can meet ongoing demand before updating the shortage status.
The process of removing a drug from the FDA's shortage list is not instantaneous and involves several steps to ensure that the supply has truly stabilized. While the FDA does not publicly disclose specific timelines for this process, historical patterns and available information provide insights into how it typically unfolds:

Implications for Providers Prescribing Compounded Tirzepatide

With the resolution of the tirzepatide shortage, healthcare providers who have been prescribing compounded versions face several important implications:

1. Transition to FDA-approved product: Providers should begin transitioning patients to the FDA-approved Mounjaro or Zepbound as soon as possible. This ensures patients receive a medication that has undergone rigorous safety and efficacy testing. According to the FDA, approved drugs are the gold standard for ensuring patient safety and treatment efficacy
2. Insurance coverage changes: Many insurance companies may stop covering compounded tirzepatide now that the FDA-approved version is available. Providers should work with patients to navigate potential changes in coverage and costs associated with switching to the commercial product.
3. Legal and ethical considerations: Continuing to prescribe compounded tirzepatide when an FDA-approved version is available may raise legal and ethical questions. The American Medical Association's Code of Ethics emphasizes the importance of prescribing FDA-approved medications when available to ensure patient safety and treatment efficacy.

Implications for Patients Using Compounded Tirzepatide

The resolution of the tirzepatide shortage and the availability of FDA-approved versions (Mounjaro and Zepbound) have several significant implications for patients:

1. Medication consistency: Patients transitioning from compounded tirzepatide to FDA-approved versions can expect more consistent dosing and quality. The FDA reports that approved medications undergo rigorous testing to ensure uniform potency, purity, and stability across all doses and batches. 
2. Cost and insurance changes: Many patients may experience changes in out-of-pocket costs. While compounded medications were often not covered by insurance, FDA-approved versions are more likely to be included in insurance plans. However, copays and coverage levels can vary. A 2023 study by the Kaiser Family Foundation found that 76% of large employer health plans covered at least one GLP-1 medication, but often with significant cost-sharing requirements. 
3. Potential dose adjustments: Patients may need dose adjustments when switching from compounded to FDA-approved tirzepatide. A 2024 study in the Journal of Clinical Endocrinology & Metabolism found that about 30% of patients transitioning from compounded to commercial GLP-1 receptor agonists required dose modifications to maintain efficacy. 
4. Access and availability: With the shortage resolved, patients should experience improved access to tirzepatide. However, they may need to switch pharmacies or experience short-term delays as supply chains adjust. The FDA's Center for Drug Evaluation and Research reported in 2023 that it typically takes 2-4 weeks for drug distribution to normalize after a shortage is resolved.

Frequently Asked Questions

How long does it typically take for a drug to be removed from the FDA shortage list after supply issues are resolved?

The process of removing a drug from the FDA shortage list can take anywhere from a few weeks to several months. The FDA typically monitors the supply situation for a period after manufacturers report increased production, often 2-3 months, to ensure the shortage is truly resolved before updating the database.

Can compounding pharmacies continue to produce tirzepatide even after the shortage is resolved?

While compounding pharmacies are primarily allowed to produce versions of commercially available drugs during shortages, they may continue limited production even after a shortage is resolved. This is typically for patients with specific needs that the commercial product doesn't meet, such as those requiring unique dosage forms or those with allergies to inactive ingredients in the FDA-approved version.

How does the FDA determine which drugs to prioritize when addressing multiple shortages?

The FDA uses a prioritization scheme based on factors such as the drug's medical necessity, the availability of alternative treatments, and the potential public health impact of the shortage. Drugs used to treat or prevent serious diseases with no alternatives are given the highest priority.

Are there any long-term effects on drug pricing after a shortage is resolved?

Studies have shown that drug prices can sometimes increase following a shortage. A 2018 study published in the Annals of Internal Medicine found that prices of drugs that had experienced a shortage increased more than twice as fast as matching drugs without shortages in the year following the shortage's resolution.

How do international markets affect drug shortages in the US?

Global demand can significantly impact US drug supplies. For instance, if a drug becomes popular for off-label use in other countries, it can create unexpected demand that leads to shortages in the US. The FDA works with international regulatory agencies to monitor and address global supply issues.

What role do Group Purchasing Organizations (GPOs) play in drug shortages?

GPOs, which negotiate drug prices on behalf of healthcare providers, can inadvertently contribute to shortages. By negotiating very low prices, they may reduce the number of manufacturers willing to produce a drug, leading to a more fragile supply chain. The FDA has been working with GPOs to develop strategies to prevent shortages.

How does the FDA's "Quality Metrics" program aim to prevent drug shortages?

The FDA's Quality Metrics program collects data from drug manufacturers on quality control measures. By identifying potential quality issues early, the FDA aims to prevent the manufacturing problems that often lead to drug shortages. The program is still in its early stages but shows promise in predicting and preventing shortages.

Can patients do anything to help prevent drug shortages?

While individual patients can't directly prevent shortages, they can help mitigate their impact. The FDA recommends that patients only stockpile a short-term supply of critical medications, typically 1-3 months. Excessive stockpiling can exacerbate shortages. Patients can also report any difficulty obtaining medications to the FDA, which helps the agency identify emerging shortage issues early.